Your browser doesn't support javascript.
loading
Enhancing the avidity of a human recombinant anti-HIV-1 monoclonal antibody through oligomerization.
Tsai, P K; Burke, C J; Irwin, J W; Bruner, M W; Tung, J S; Hollis, G F; Mark, G E; Kessler, J A; Boots, L J; Conley, A J.
Affiliation
  • Tsai PK; Department of Pharmaceutical Research, Merck Research Laboratories, West Point, PA 19486, USA.
J Pharm Sci ; 84(7): 866-70, 1995 Jul.
Article in En | MEDLINE | ID: mdl-7562439
ABSTRACT
The oligomerization by chemical cross-linking of a recombinant human antiviral monoclonal antibody (MAb), r447-1, and its characterization are described. This MAb binds to an epitope residing in the hypervariable V3 region of the envelope protein (gp120/160) of HIV-1. A dimeric form of this MAb displays enhanced avidity and was found to be capable of neutralizing a greater variety of lymphoid cell culture-adapted HIV-1 variants and HIV-1 primary isolates than its monomeric form. The superior binding and breadth of reactivity of this antibody suggests it may have utility as a therapeutic and/or prophylactic agent, if it possesses an appropriate safety and immunogenicity profile.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: HIV-1 / Antibodies, Monoclonal Limits: Humans Language: En Journal: J Pharm Sci Year: 1995 Document type: Article Affiliation country: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: HIV-1 / Antibodies, Monoclonal Limits: Humans Language: En Journal: J Pharm Sci Year: 1995 Document type: Article Affiliation country: United States